Compounds > amikacin
Page last updated: 2024-08-23

amikacin and Vestibular Diseases

amikacin has been researched along with Vestibular Diseases in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (42.86)29.6817
2010's4 (57.14)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bach, A; Chen, KS; Shoup, A; Winick, NJ1
Bach, A; Chen, K; Shoup, A; Winick, N1
Castagnola, E; Dallorso, S; Haupt, R1
Eather, GW; Ellender, CM; Law, DB; Thomson, RM1
Zagólski, O2
Elidan, J; Freeman, S; Priner, R; Sohmer, H1

Trials

1 trial(s) available for amikacin and Vestibular Diseases

ArticleYear
Vestibular system in infants after systemic therapy with amikacin.
    Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale, 2008, Volume: 37, Issue:4

    Topics: Amikacin; Anti-Bacterial Agents; Evoked Potentials, Auditory, Brain Stem; Female; Humans; Infant; Male; Statistics, Nonparametric; Vestibular Diseases; Vestibular Function Tests

2008

Other Studies

6 other study(ies) available for amikacin and Vestibular Diseases

ArticleYear
Hearing loss and vestibular dysfunction among children with cancer after receiving aminoglycosides.
    Pediatric blood & cancer, 2013, Volume: 60, Issue:11

    Topics: Amikacin; Aminoglycosides; Antineoplastic Agents; Child; Child, Preschool; Female; Hearing Loss; Humans; Male; Neoplasms; Vestibular Diseases; Vestibular Evoked Myogenic Potentials

2013
Invited reply to amikacin ototoxicity in children with cancer: the problem is the administration schedule.
    Pediatric blood & cancer, 2014, Volume: 61, Issue:2

    Topics: Amikacin; Aminoglycosides; Antineoplastic Agents; Female; Hearing Loss; Humans; Male; Neoplasms; Vestibular Diseases

2014
Administration schedule and ototoxicity of amikacin in children with cancer.
    Pediatric blood & cancer, 2014, Volume: 61, Issue:2

    Topics: Amikacin; Aminoglycosides; Antineoplastic Agents; Female; Hearing Loss; Humans; Male; Neoplasms; Vestibular Diseases

2014
Safety of IV amikacin in the treatment of pulmonary non-tuberculous mycobacterial disease.
    Respirology (Carlton, Vic.), 2016, Volume: 21, Issue:2

    Topics: Acute Kidney Injury; Administration, Intravenous; Adult; Aged; Amikacin; Anti-Bacterial Agents; Female; Hearing Loss; Humans; Lung Diseases; Male; Middle Aged; Mycobacterium avium; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Retrospective Studies; Treatment Outcome; Vestibular Diseases

2016
Vestibular system in infants after systemic aminoglycoside therapy.
    International journal of pediatric otorhinolaryngology, 2007, Volume: 71, Issue:11

    Topics: Amikacin; Aminoglycosides; Bacterial Infections; Caloric Tests; Evoked Potentials, Auditory; Evoked Potentials, Auditory, Brain Stem; Female; Humans; Infant; Injections, Intravenous; Male; Time Factors; Vestibular Diseases

2007
Objective method for differentiating between drug-induced vestibulotoxicity and cochleotoxicity.
    Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 2001, Volume: 22, Issue:1

    Topics: Amikacin; Animals; Anti-Bacterial Agents; Cochlear Diseases; Endolymph; Evoked Potentials, Auditory, Brain Stem; Feasibility Studies; Guinea Pigs; Hair Cells, Auditory; Time Factors; Vestibular Diseases

2001